Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants

Published:2018-04 Issue: Volume:118 Page:128-133
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Li Yan,Zhang Tongtong,Zhang Jing,Li Wenbin,Yuan Pei,Xing Puyuan,Zhang Zhou,Chuai Shannon,Li Junling,Ying Jianming

Funder

Youth Backbone Program

CAMS

Beijing Hope Run Special Fund of Cancer Foundation of China

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. The biology and treatment of EML4-ALK non-small cell lung cancer;Sasaki;Eur. J. Cancer,2010

3. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only;Togashi;PLoS One,2012

4. A novel fusion of TPR and ALK in lung adenocarcinoma;Choi;J. Thorac. Oncol.,2014

5. BIRC6-ALK, a novel fusion gene in ALK Break-Apart FISH-Negative lung adenocarcinoma, responds to crizotinib;Shan;J. Thorac. Oncol.,2015

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term survival following molecular-targeted therapy for intramedullary non-small-cell lung cancer metastasis;Surgical Neurology International;2024-08-30

2. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE);Journal of Thoracic Oncology;2024-06

3. Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing;Expert Review of Anticancer Therapy;2024-04-02

4. Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy;Lung Cancer;2024-03

5. Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB-ALK rearrangement and KRAS G12C mutation by sintilimab combined with anlotinib;Frontiers in Oncology;2024-02-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3